(SeaPRwire) –   FOSTER CITY, Calif., April 24, 2026 — OrthoTrophix, Inc., a private biopharmaceutical firm, has announced new clinical results showing a significant link between the shape of femoral subchondral bone, measured by B-score, and meniscal pathology in patients suffering from knee osteoarthritis (KOA). These results strengthen the evidence for bone-shape metrics as reliable, quantitative structural indicators that can reflect the severity and advancement of KOA.

The company is presenting a late-breaking abstract titled “WORMS-Defined Meniscal Pathology is Associated with Femoral Bone-Shape Change, with Attenuation in IA TPX-100 Treated Knees” (Poster #665) at the Osteoarthritis Research Society International (OARSI) 2026 World Congress in West Palm Beach, Florida (April 23 – 26, 2026). The poster will be on display April 24 – 25.

WORMS (Whole Organ Magnetic Resonance Imaging Score) is a semi-quantitative MRI method used to evaluate structural features of KOA across various joint tissues. In this retrospective analysis, femoral bone shape—quantified by the B-score—showed statistically significant correlations with WORMS-defined meniscal pathology across different timepoints.

The meniscus is essential for joint stability and load distribution, and its degradation is a recognized factor in the progression of KOA. These findings suggest that meniscal damage and changes in subchondral bone shape develop together in KOA, likely reflecting shared biomechanical pathways related to joint degeneration and altered load transmission.

Longitudinal data indicated that in placebo-treated knees, the link between meniscal pathology and bone-shape changes intensified over time, aligning with progressive structural coupling during the course of the disease. In contrast, knees treated with TPX-100 showed a stabilization of bone-shape changes and a reduction in this relationship. While exploratory, these results suggest that TPX-100 may impact the structural progression of KOA.

OrthoTrophix is also showcasing a second abstract, “More Severe Baseline Meniscal Pathology Predicts Greater, Sustained Response to IA TPX-100: A WORMS Analysis from a Randomized Trial” (Poster #664). This study found that patients with more advanced baseline pathology saw greater and more lasting improvements in patient-reported outcomes (PROs), such as WOMAC Function, after treatment with TPX-100 compared to those receiving a placebo. These results suggest that baseline meniscal pathology could serve as a potential effect modifier, identifying patients who are most likely to benefit from TPX-100.

“These findings offer new insights into the connection between subchondral bone remodeling and meniscal pathology in OA,” stated Dawn McGuire, M.D., Chief Medical Officer of OrthoTrophix. “Together, these analyses provide imaging-based evidence linking these factors in KOA and support the continued evaluation of TPX-100 as a potential modifier of structural disease progression. These results may also help refine patient selection strategies for future clinical trials and support the use of femoral bone-shape metrics as quantitative measures in KOA.”

About OrthoTrophix, Inc.

OrthoTrophix, Inc., based in the San Francisco Bay Area, is a private biopharmaceutical company focused on creating first-in-class therapies to protect joint integrity in osteoarthritis and related conditions. Founded in 2011, OrthoTrophix is advancing targeted disease-modification strategies to slow disease progression and improve patient outcomes. The company has partnered with American Regent, Inc. (https://americanregent.com/) for its DMOAD candidate, TPX-100, in the U.S. market while retaining rights for the rest of the world.

This press release contains “forward-looking” statements. These statements involve risks and uncertainties that may cause actual results to differ from those projected. The forward-looking statements regarding product development are not guaranteed. OrthoTrophix assumes no obligation to update any forward-looking statement based on new information or future events. These statements should be evaluated alongside the various uncertainties affecting the company’s business.

Company Contact
Yoshi Kumagai
President and CEO
Tel: (510) 488-3824

Source: OrthoTrophix, Inc.